Entity

Time filter

Source Type

Shibukawa, Japan

Kasahara Y.,Fukui Saiseikai Hospital | Kawai M.,Tohoku University | Tsuji I.,Tohoku University | Tohno E.,University of Tsukuba | And 4 more authors.
Breast Cancer | Year: 2013

Background The US Preventative Services Task Force assesses the efficacy of breast cancer screening by the sum of its benefits and harms, and recommends against routine screening mammography because of its relatively great harms for women aged 40-49 years. Assessment of the efficacy of screening mammography should take into consideration not only its benefits but also its harms, but data regarding those harms are lacking for Japanese women. Methods In 2008 we collected screening mammography data from 144,848 participants from five Japanese prefectures by age bracket to assess the harms [false-positive results, performance of unnecessary additional imaging, fine-needle aspiration cytology (FNA), and biopsy and its procedures]. Results The rate of cancer detected in women aged 40-49 years was 0.28%. The false-positive rate (9.6%) and rates of additional imaging by mammography (5.8%) and ultrasound (7.3%) were higher in women aged 40-49 years than in the other age brackets. The rates of FNA (1.6%) and biopsy (0.7%) were also highest in women aged 40-49 years. However, they seemed to be lower than the rates reported by the Breast Cancer Surveillance Consortium (BCSC) and other studies in the US. Conclusions The results, although preliminary, indicate the possibility that the harms of screening mammography for Japanese women are less than those for American women. © The Japanese Breast Cancer Society 2012. Source


Takeyoshi I.,Gunma University | Makita F.,National Nishi Gunma Hospital | Tanahashi Y.,Shibukawa General Hospital | Iwazaki S.,Tatebayashi Kosei Hospital | And 17 more authors.
Anticancer Research | Year: 2011

Background: Paclitaxel and doxifluridine (5′-DFUR) have distinct mechanisms of action and toxicity profiles. This study evaluated the antitumor activity and toxicities of combination chemotherapy with these drugs in patients with advanced/recurrent gastric cancer (AGC). Patients and Methods: Patients with histologically confirmed AGC, which was either unresectable or metastatic, were included in this study. The treatment consisted of 80 mg/m2 paclitaxel given i.v. on days 1, 8, and 15 every 4 weeks, and 533 mg/m 2 doxifluridine given orally on days 1-5 every week. Results: One hundred and four patients were evaluated for toxicity and 93 patients were evaluated for a therapeutic response. The overall response rate was 33.3% (1st line: 41.7%, 2nd line: 25.0%), including a complete remission in two patients, a partial remission in 29, stable disease in 39, progressive disease in 17; the response was not evaluable in six patients. The median overall survival was 287 days. Commonly observed grade 3/4 adverse events were leukopenia (13.5%), anorexia (3.8%), fatigue (3.8%) and diarrhea (2.9%). Conclusion: Paclitaxel and doxifluridine combination chemotherapy is a well-tolerated and convenient treatment regimen that can be given on an outpatient basis with promising efficacy for AGC. Source


Takeyoshi I.,Gunma University | Makita F.,Nishi Gunma National Hospital | Iwazaki S.,Tatebayashi Kosei Hospital | Ishikawa H.,Fujiyoshida Municipal Medical Center | And 16 more authors.
Anticancer Research | Year: 2011

Background: The efficacy of systemic chemotherapy for peritoneal dissemination of gastric cancer remains unclear. The efficacy of weekly paclitaxel in combination with doxifluridine (5′-DFUR) in gastric cancer patients with malignant ascites was evaluated. Patients and Methods: Patients with histologically confirmed gastric cancer with ascites were eligible. The treatment consisted of paclitaxel intravenously (i.v.) administered at 80 mg/m 2 on days 1, 8 and 15 every 4 weeks, and doxifluridine administered orally at 533 mg/m 2 on days 1-5 every week. The response rate for patients with ascites was determined based on the Japanese Classification of Gastric Carcinoma. Also, the concentration of paclitaxel in the ascites was measured. Results: Twenty-four patients were investigated. The response rate (RR) was 41.7%, including complete remission (CR) and partial remission (PR) in 4 and 6 patients, respectively. The concentration of paclitaxel in the ascites was maintained between 0.01 μM and 0.05 μM until 72 hours. The median overall survival (OS) was 215 days, and 1-year survival rate was 29.2%. No severe toxicity was noted. Conclusion: Weekly paclitaxel in combination with doxifluridine is effective for gastric cancer patients with malignant ascites with an acceptable toxicity profile. Source


Kurabayashi M.,Shibukawa General Hospital | Tanahashi Y.,Shibukawa General Hospital | Okano T.,Shibukawa General Hospital | Ohki S.,Shibukawa General Hospital | And 3 more authors.
Kitakanto Medical Journal | Year: 2012

A 62-year-old male presented with appetite loss, abdominal fullness, tarry stool, and vertigo. Gastrointestinal endoscopy showed advanced gastric cancer, type 3, which was diagnosed as poorly differentiated adenocarcinoma with severe pyloric stenosis. Computed tomography (CT) showed hugely enlarged lymph nodes in the para-aortic region. He was diagnosed with gastric cancer stage IV and treated with paclitaxel chemotherapy weekly. However, the treatment was ineffective. A nasogastric tube was required for persistent vomiting with gastric outlet obstruction. We recommended a gastroje-junostomy bypass operation, but the patient refused. After obtaining informed consent, a WallFlex stent was inserted, but did not relieve the obstruction. Endoscopy showed that the stent was obstructed with tumor ingrowth. An UltraFlex covered stent was inserted within the WallFlex stent and was effective. Subsequently, the patient was able to eat solid food for 9 months, received chemotherapy, and died 11 months after stent insertion. Stent therapy should be considered for palliative care in gastric outlet obstruction caused by gastric cancer. Source

Discover hidden collaborations